Wells Fargo Maintains Equal-Weight on Conmed, Lowers Price Target to $39
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Larry Biegelsen maintains Conmed (NYSE:CNMD) with a Equal-Weight and lowers the price target from $42 to $39.
Wells Fargo analyst Larry Biegelsen maintains Conmed (NYSE:CNMD) with a Equal-Weight and lowers the price target from $42 to $39.